Conba Usa Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CONBA USA
CONBA USA has two approved drugs.
Drugs and US Patents for Conba Usa
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Conba Usa | ACETYLCYSTEINE | acetylcysteine | SOLUTION;INHALATION, ORAL | 214177-002 | Mar 14, 2025 | AN | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Conba Usa | ENTECAVIR | entecavir | TABLET;ORAL | 216857-002 | Dec 23, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Conba Usa | ENTECAVIR | entecavir | TABLET;ORAL | 216857-001 | Dec 23, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

